Oxford Drug Design is a biotechnology company focused on AI-driven drug discovery. Founded in 2001 as InhibOx and based in Oxford, UK, the company leverages expertise in tRNA synthetase enzyme targeting and machine learning to create innovative therapeutics for oncology, infectious diseases, and other significant health conditions.The company employs advanced techniques such as neural networks and virtual screening to enhance lead optimization. Its pipeline includes antibiotic programs developed with machine learning support and preclinical oncology candidates targeting synthetase pathways. Oxford Drug Design also offers drug discovery services, including computational screening and analog design for external partners. The company collaborates with organizations like CARB-x to address antimicrobial resistance and has received recognition in the AI and biotechnology sectors. Led by experienced professionals, including CEO Dr. Alan D. Roth and R&D leader Dr. Paul Finn, Oxford Drug Design combines academic heritage with a strong focus on innovative drug development.
7 Reviews
0 Reviews
Not Rated.
Write the first review
Help other software buyers make informed decisions.
It looks like Oxford Drug Design hasn’t been reviewed yet. If you are a customer of theirs or have used their services in the past, why don’t you be the first to leave a review and tell other visitors about your experience?
Signing in with LinkedIn shows that your review is genuine and written by a real person. We can't and wouldn't post anything to your LinkedIn account or to your connections.
Don't use LinkedIn? You can write unverified reviews too.
Thanks for writing a review, please allow 48 hours for it to appear on the site.